Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Protalix Biotherapeutics And Chiesi Global Rare Diseases Announce Final Dosing Of Last Patient In Phase III BALANCE Clinical Trial PRX-102 For Treatment Of Fabry Disease


Benzinga | Oct 15, 2021 08:39AM EDT

Protalix Biotherapeutics And Chiesi Global Rare Diseases Announce Final Dosing Of Last Patient In Phase III BALANCE Clinical Trial PRX-102 For Treatment Of Fabry Disease






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC